Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to include ex vivo T lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
Horizon Discovery Group enters exclusive partnership with C4X Discovery Holdings
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc, a pioneering drug discovery company, to validate targets and develop next-generation oncology drugs.
Horizon Discovery partners with Biocartis to provide reference standards for Idylla™ assay
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces that it has developed a set of precisely defined cell line-derived reference standards to support Biocartis’ recently launched Idylla™ microsatellite instability (MSI) Assay (1).
Horizon Discovery Myeloid DNA Reference Standard supports genetic testing of leukemia
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. It is the first-to-market large cell line-derived reference standard for myeloid blood cancers.
Horizon Discovery Edit-R crRNA libraries adopted by AstraZeneca
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces AstraZeneca has adopted its Edit-R™ crRNA libraries as part of AstraZeneca’s drive to establish a functional genomics discovery platform.
Horizon Discovery announces collaboration on single cell RNAseq-linked CRISPR screening
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces that it has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target identification and validation.
Horizon Discovery appoints Terry Pizzie as Chief Executive Officer
Horizon Discovery Group plc), a global leader in gene editing and gene modulation technologies, is pleased to announce the appointment of Terry Pizzie as Chief Executive Officer and Board Director with immediate effect.
Horizon and Pirbright Institute support research into improvement of vaccine yields
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, today announces that it has extended its biomanufacturing capabilities through an agreement with The Pirbright Institute to jointly work on a research programme aimed at deploying cell engineering to increase the yields of livestock vaccines.
Horizon Discovery’s Bioproduction cell line used as part of a successful drug (IND) filing
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, today announces that one of the licensees to its Bioproduction cell line technology has used Horizon’s cell line as part of a successful Investigational New Drug (IND) filing with the United States Food and Drug Administration (USFDA).
Horizon Discovery announces leadership changes
Horizon Discovery Group plc (LSE: HZD), a global leader in gene editing and gene modulation technologies, today announces that Dr Darrin M. Disley has decided to step down as Chief Executive Officer in order to pursue other business interests.
Horizon Discovery’s Dharmacon introduces Edit-R CRISPRa reagent platform
Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announced the launch of its reagent platform for CRISPR activation (CRISPRa) from its recently acquired Dharmacon™ business. This is the latest addition to the company’s market-leading Edit-R™ portfolio for CRISPR-Cas9 genome engineering.
Horizon Discovery partners with The Michael J. Fox Foundation for Parkinson’s research
Horizon Discovery, a global leader in gene editing and gene modulation technologies, in partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF), today introduced two new gene knock-out and knock-in rat models for investigating the role of alpha-synuclein in brain function and Parkinson’s disease (PD) pathogenesis.
Horizon Discovery Group delivers consistent strong growth
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, is positioned for additional scale following its transformational acquisition of GE Healthcare Dharmacon, Inc. The company has announced its interim results for the six months ended 30 June 2017.
Horizon Discovery introduces OncoSpan, the world’s largest reference standard for oncology
Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announces the launch of OncoSpan, a novel cell line-derived multiplex DNA Reference Standard to support the validation of Next Generation Sequencing (NGS) assays.
Horizon Discovery launches genome-wide CRISPRi and CRISPRa screening services
Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announces that it has expanded its functional genomic screening portfolio to include first-to-market CRISPRi (interference) and CRISPRa (activation) screening services.
Horizon Discovery releases CHO genome sequence to drive innovation in bioproduction
Horizon Discovery, a global leader in the application of gene editing technologies, today announced it has released a complete, high-quality, well annotated sequence of its GS Knockout CHO-K1 bioproduction cell line. The sequence will be made available publicly via the Ensembl website at EMBL-EBI, to serve the community as a resource to drive research and innovation in bioproduction at Horizon…
Horizon Discovery Group plc acquires GE Healthcare Dharmacon, Inc. for $85 million
Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing technologies, today announces that it has entered into an agreement to acquire Dharmacon from General Electric Company for a total consideration of $85 million (£65 million), subject to a working capital adjustment at completion of the Acquisition (Completion).
Horizon Discovery takes exclusive licence for novel gene editing technology platform
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces the completion of licensing agreements with all joint patent holders to provide exclusive worldwide rights to a novel transposon-based gene editing technology platform.
Horizon Discovery’s reference standards support assay development and clinical trial
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces the use of its Reference Standards in a recent successful premarket approval application (PMA) filing with the US FDA for a companion diagnostic in oncology by a leading next generation sequencing company.
Abcam plc extends licence and supply agreement with Horizon Discovery
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces that Abcam plc, a global leader in the supply of research antibodies, has extended a pre-existing licence and supply agreement between the two companies by exercising an exclusivity provision for the period from July 2017 through June 2018.
Horizon Discovery’s RNA reference standards endorsed for use in cancer research testing
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today notes its complete RNA reference standards product range have been endorsed by Thermo Fisher Scientific for use in its Ion Ampliseq and Oncomine fusion assays for cancer research.
Horizon Discovery announces progress of its gene and cell therapy platform
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces progress of its gene and cell therapy platform for contract service and therapeutic applications. The new offering will make use of Horizon’s extensive suite of gene editing technologies, including CRISPR and its proprietary rAAV and Transposon technologies, to edit pluripotent stem…
ATUM and Horizon Discovery collaborate to speed bioproduction cell line development
ATUM (formerly DNA2.0, Inc.) and Horizon Discovery, the world leader in the application of gene editing technologies, today announced they have signed a cross-licence agreement for Horizon’s CHO SOURCE platform and ATUM’s vector technology to speed development of highly productive stable cell lines for drug development.
Horizon Discovery Group plc continues high growth trajectory
Horizon Discovery Group plc, a world leader in the application of gene editing technologies, announces its preliminary results for the year ended 31 December 2016.
Horizon Discovery announces update on its immuno-oncology platform
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, today provides an update on the performance of its Immuno-Oncology platform, which combined represents over £1.5 million in current and ongoing product sales and contract research projects in FY17 to date, with a very strong order book in place for the remainder of the year.